Teva Calls 5.550% Senior Notes Due 2016 for Redemption

  Teva Calls 5.550% Senior Notes Due 2016 for Redemption

Business Wire

JERUSALEM -- March 1, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its
finance subsidiary Teva Pharmaceutical Finance Company, LLC has called for
redemption its approximately $500 million outstanding principal amount of
5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3). The redemption is being
funded with cash on hand.

The redemption date will be March 22, 2013, and the redemption price will
equal the principal amount of the notes plus a make whole premium calculated
in accordance with the terms of the applicable indenture. On the redemption
date, the redemption price, together with accrued and unpaid interest from
February 1, 2013, to, but excluding, the redemption date, will become due and
payable on the notes.

Details concerning the redemption price and the other terms and conditions of
the redemption will be more fully described in a Notice of Redemption being
provided to registered holders of the notes by The Bank of New York Mellon, as
trustee. Holders of notes who have questions should contact Joellen McNamara
of The Bank of New York Mellon at 1-212-815-5587 or via email at, or Teva’s investor relations department at
(215) 591-8912 or (011) 972-3-926-7656.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.


Teva Pharmaceutical Industries Ltd.
United States
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
Tomer Amitai, 972 (3) 926-7656
Hadar Vismunski-Weinberg, 972 (3) 926-7687
United States
Denise Bradley, 215-591-8974
Press spacebar to pause and continue. Press esc to stop.